Publications AVISE CTD / AVISE Lupus / AVISE CB-CAPs AVISE Lupus is indicated for the diagnosis of suspected SLE patients. AVISE CTD is indicated for differential diagnosis of autoimmune connective tissue diseases. Clinical Validity A multianalyte assay panel with cell-bound complement activation products predicts transition of probable lupus to American College of Rheumatology-classified lupus. Ramsey-Goldman R et al. ACR Open Rheumatology 2021 Complement activation occurs in patients with probable systemic lupus erythematosus and may predict progression to ACR classified SLE. Ramsey-Goldman R et al. Arthritis & Rheumatology 2020 Cell-bound complement activation products associate with lupus severity in SLE. Arriens C et al. Lupus Science & Medicine 2020 Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity. Hui-Yen J et al. Lupus 2018 Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. Wallace D et al. Lupus Science & Medicine 2016 Cell-bound complement activation products in systemic lupus erythematosus. Putterman C et al. Lupus Science & Medicine 2014 Clinical Utility A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus. Alexander RV et al. Lupus Science & Medicine 2021 Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression. Liang E et al. Lupus Science & Medicine 2020 Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. Wallace D et al. Lupus Science & Medicine 2019 The AVISE Lupus test and cell-bound complement activation products aid the diagnosis of systemic lupus erythematosus. Mossell J et al. The Open Rheumatology Journal 2016 Health Economic Outcome Research Evaluation of the economic benefit of earlier systemic lupus erythematosus (SLE) diagnosis using a multivariate assay panel (MAP). Clarke A et al. ACR Open Rheumatology 2020 Analytical Validity Validation of multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus. Dervieux T et al. Journal of Immunological Methods 2017 Review Articles A Review of Complement Activation in SLE. Weinstein A et al. Current Rheumatology Reports 2021 Cell-bound complement activation products in SLE. Ramsey-Goldman R et al. Lupus Science and Medicine 2017 Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification Ahearn J et al. Expert Review of Clinical Rheumatology 2017 Case Study Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPs). Lamichhane D et al. Lupus 2016 AVISE SLE Monitor / AVISE PC4d AVISE SLE Monitor is indicated for the ongoing assessment of SLE disease activity. PC4d is indicated for diagnosed SLE patients as a marker associated with thrombosis. Clinical Validity Platelet-bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in systemic lupus. Gartshteyn Y et al. Clinical Immunology 2021 Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus Svenungsson E et al. Rheumatology 2020 Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE. Petri M et al. Lupus Science & Medicine 2019 Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Merrill JT et al. Lupus Science & Medicine 2018 Performance characteristics of different anti-double-stranded DNA antibody assays in the monitoring of systemic lupus erythematosus. Mahler M et al. Journal of Immunology Research 2017 Reduction in erythrocyte-bound complement activation products and titers of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. Buyon J et al. Lupus Science & Medicine 2016 Anti-C1q antibodies in systemic lupus erythematosus Orbai AM et al. Lupus 2015 Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus. Kao AH et al. Transitional Stroke Research 2014 Anti-C1q antibodies have a higher correlation with flares of lupus nephritis than other serum markers. Akhter E et al. Lupus 2012 Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Kao A et al. Arthritis & Rheumatology 2010 AVISE MTX / AVISE Touch Avise MTX is indicated for RA patients receiving Methotrexate therapy as an objective measure of therapeutic exposure. Clinical Validity Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept. Dervieux T et al. Annals of the Rheumatic Diseases 2019 Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: A 76-week prospective study Takahashi C et al. RMD Open 2017 Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis. Dervieux T et al. Annals of the Rheumatic Diseases 2013 Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Dervieux T et al. Rheumatology 2010 Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Dervieux T et al. Arthritis & Rheumatology 2006 Pharmacogentic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentered cross-sectional observation study Dervieux T et al. Annals of the Rheumatic Diseases 2005 Analytical Validity Transition of methotrexate polyglutamate drug monitoring assay from venipuncture to capillary blood-based collection method in rheumatic diseases. Brady K et al. The Journal of Applied Laboratory Medicine 2019 Review Articles Methotrexate: Optimizing the efficacy in rheumatoid arthritis. therapeutic advances in musculoskeletal disease. Braun J et al. Therapeutic Advances in Musculoskeletal Disease 2011 Toward a better understanding of methotrexate. Kremer J et al. Arthritis & Rheumatology 2004 AVISE HCQ / AVISE Touch AVISE HCQ is indicated for SLE patients receiving Hydroxychloroquine therapy as an objective measure of drug exposure. Clinical Validity Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Petri M et al. Arthritis & Rheumatology 2020 A prospective international study on adherence to treatment in 305 patients with flaring SLE: Assessment by drug levels and self-administered questionnaires. Costedoat-Chalumeau N et al. Clinical Pharmacology and Therapeutics 2019 Hydroxychloroquine in systemic lupus erythematosus: Results of a French multicentre controlled trial (PLUS Study). Costedoat-Chalumeau N et al. Annals of the Rheumatic Diseases 2013 Analytical Validity Capillary blood collected on volumetric absorptive microsampling (VAMS) device for monitoring hydroxychloroquine in rheumatoid arthritis patients. Qu Y et al. Journal of Pharmaceutical and Biomedical Analysis 2017 AVISE HCQ Review Articles Hydroxychloroquine blood levels in systemic lupus erythematosus: Clarifying dosing controversies and improving adherence. Durcan L et al. The Journal of Rheumatology 2015 Anti-Carbamylated Protein Antibodies (Anti-CarP) Reevaluating serologic markers of poor prognostic factors in rheumatoid arthritis. Weinstein A et al. The Journal of Rheumatology 2019 Association of the presence of anti-carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome: Data from the French ESPOIR cohort. Truchetet ME et al. Arthritis & Rheumatology 2017 Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Shi J et al. PNAS 2011 Selected Abstracts Association of HCQ blood levels with Type 1 and 2 SLE activity Sun K et al. Arthritis & Rheumatology 2021 Cell-bound Complement Activation Products (CB-CAPs) predicts Type 1 SLE activity Rogers J et al. Arthritis & Rheumatology 2021 The incremental clinical utility of a multianalyte assay panel with cell-bound complement activation products versus a traditional ANA testing strategy for the diagnosis and treatment of SLE. O'Malley T et al. Arthritis & Rheumatology 2021 Multianalyte assay panel with cell-bound complement activation products demonstrates Clinical utility for the diagnosis and treatment of systemic lupus erythematosus role of platelet C4d in thrombosis and lupus nephritis. Alexander R et al. Arthritis & Rheumatology 2021 Role of platelet C4d in thrombosis and lupus nephritis. Petri M et al. Arthritis & Rheumatology 2020 Platelet-bound C4d is associated with an increased risk of arterial and venous thromboses in SLE. Gartshteyn Y et al. Arthritis & Rheumatology 2020 Agreement of hydroxychloroquine blood levels between a university and commercial laboratory. Petri M et al. Arthritis & Rheumatology 2020 Enhanced methotrexate polyglutamation in Japanese as compared to Caucasian rheumatoid arthritis patients starting methotrexate. Dervieux T et al. Arthritis & Rheumatology 2019 Diagnostic performances of antibodies against carbamylated proteins in U.S. rheumatoid arthritis and other autoimmune rheumatic diseases. Shi J et al. Arthritis & Rheumatology 2018 Complement activation in peripheral blood in relation to lupus, antiphospholipid and rheumatoid arthritis autoantibodies: Insights from clinical laboratory evaluations. Dervieux T et al. Arthritis & Rheumatology 2017 Cell-bound complement activation products distinguish systemic lupus erythematosus from other diseases among patients with high antinuclear antibody titers and normal complement. Wallace D et al. Arthritis & Rheumatology 2017 ©2021 Exagen Inc. | All Rights Reserved SA1168